安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Provides Business Update and 2025 Outlook
Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Reports First Quarter 2025 Financial Results and Provides . . .
Rigel Pharmaceuticals, Inc (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer
- Rigel Announces R289 Granted Fast Track Designation by the FDA for . . .
SOUTH SAN FRANCISCO, Calif , Dec 2, 2024 PRNewswire -- Rigel Pharmaceuticals, Inc (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the…
- Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting . . .
Rigel's poster presentations will include data for GAVRETO ® (pralsetinib) for the treatment of metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), including final data from the Phase 1 2 ARROW study, and REZLIDHIA ® (olutasidenib) for the treatment of relapsed or refractory (R R) mutated
- Pipeline :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases
- Investor Relations :: Rigel Pharmaceuticals, Inc. (RIGL)
Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases
- Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib . . .
"The resolution of this patent litigation underscores the strength of Rigel's intellectual property protecting TAVALISSE, an innovative treatment for people with immune thrombocytopenia," said Raul Rodriguez, Rigel's president and CEO
|
|
|